Viatris and Idorsia enter research and development collaboration
Betsy Goodfellow | February 28, 2024 | News story | Research and Development | Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration.
Under the terms of this agreement, Viatris will receive exclusive development and commercialisation rights to two phase 3 assets, it will also have the option to add further innovative assets in the future.
Assets included in this collaboration currently include selatogrel, a self-administered treatment for patients with a history of acute myocardial infarction (AMI) or heart attacks, and cenerimod, an immunology asset for the treatment of systemic lupus erythematosus (SLE).
Scott A Smith, Viatris’ chief executive officer, commented: “I am extremely pleased with our global research and development collaboration with Idorsia. We are connecting Idorsia’s proven, highly productive drug development team and innovation engine with Viatris’ strong global infrastructure and experience to focus on two late-stage potential blockbuster assets with long-dated patent protection. I believe that together we will be able to execute on the potential of these global assets, and any future assets, as we work to deliver on our goal of building a more durable, predictable portfolio on the foundation of our strong base business, and that selatogrel and cenerimod can become meaningful components of Viatris’ business over the long term. As I have said previously, in addition to continuing to develop the three core therapeutic areas that we identified—ophthalmology, dermatology and gastroenterology—we are also going to be opportunistic in seeking out assets that we believe fit our company well and have the potential to contribute significantly to our future revenue growth. Entering into this type of global research and development partnership structure with Idorsia is a great example of our disciplined approach to capital allocation.”
Betsy Goodfellow
Related Content
Idorsia reveals it is working with Neurocrine on new epilepsy drug deal
Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and …
Mylan and Upjohn merger will create a new entity: Viatris
The name for the new company emerging out of the merger between Pharma firm Mylan …
UCB and Biogen’s lupus drug falls short at Phase 2b
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab …